

RESEARCH ARTICLE

# Non-O ABO blood group genotypes differ in their associations with *Plasmodium falciparum* rosetting and severe malaria

D. Herbert Opi<sup>1,2\*</sup>, Carolyne M. Ndila<sup>1</sup>, Sophie Uyoga<sup>1</sup>, Alex W. Macharia<sup>1</sup>, Clare Fennell<sup>2</sup>, Lucy B. Ochola<sup>1</sup>, Gideon Nyutu<sup>1</sup>, Bethseba R. Siddondo<sup>1</sup>, John Ojal<sup>1</sup>, Mohammed Shebe<sup>1</sup>, Kennedy O. Awuondo<sup>1</sup>, Neema Mturi<sup>1</sup>, Norbert Peshu<sup>1</sup>, Benjamin Tsofa<sup>1</sup>, Gavin Band<sup>3</sup>, Kathryn Maitland<sup>1,4</sup>, Dominic P. Kwiatkowski<sup>3†</sup>, Kirk A. Rockett<sup>3</sup>, Thomas N. Williams<sup>1,4</sup>, J. Alexandra Rowe<sup>2</sup>

**1** Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya, **2** Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom, **3** Wellcome Centre for Human Genetics, Oxford, United Kingdom, **4** Institute for Global Health Innovation, Department of Surgery and Cancer, Imperial College, London, United Kingdom

☞ These authors contributed equally to this work.

† Deceased.

✉ Current address: Burnet Institute, Melbourne, Victoria, Australia

\* [herbert.opi@burnet.edu.au](mailto:herbert.opi@burnet.edu.au)



**OPEN ACCESS**

**Citation:** Opi DH, Ndila CM, Uyoga S, Macharia AW, Fennell C, Ochola LB, et al. (2023) Non-O ABO blood group genotypes differ in their associations with *Plasmodium falciparum* rosetting and severe malaria. *PLoS Genet* 19(9): e1010910. <https://doi.org/10.1371/journal.pgen.1010910>

**Editor:** Susana Campino, London School of Hygiene & Tropical Medicine, UNITED KINGDOM

**Received:** September 30, 2022

**Accepted:** August 8, 2023

**Published:** September 14, 2023

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pgen.1010910>

**Copyright:** © 2023 Opi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** De-identified participant data, in vitro datasets and numerical data for all the figures and summary statistics used during the current study are available at <https://doi.org/10.1371/journal.pgen.1010910>

## Abstract

Blood group O is associated with protection against severe malaria and reduced size and stability of *P. falciparum*-host red blood cell (RBC) rosettes compared to non-O blood groups. Whether the non-O blood groups encoded by the specific ABO genotypes AO, BO, AA, BB and AB differ in their associations with severe malaria and rosetting is unknown. The A and B antigens are host RBC receptors for rosetting, hence we hypothesized that the higher levels of A and/or B antigen on RBCs from AA, BB and AB genotypes compared to AO/BO genotypes could lead to larger rosettes, increased microvascular obstruction and higher risk of malaria pathology. We used a case-control study of Kenyan children and *in vitro* adhesion assays to test the hypothesis that “double dose” non-O genotypes (AA, BB, AB) are associated with increased risk of severe malaria and larger rosettes than “single dose” heterozygotes (AO, BO). In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference ( $p = 0.02$ , Wald test). *In vitro* experiments with blood group A-preferring *P. falciparum* parasites showed that significantly larger rosettes were formed with AA and AB host RBCs compared to OO, whereas AO and BO genotypes rosettes were indistinguishable from OO. Overall, the data show that ABO genotype influences *P. falciparum* rosetting and support the hypothesis that double dose non-O genotypes confer a greater risk of severe malaria than AO/BO heterozygosity.

[org/10.7910/DVN/A5KILM](https://doi.org/10.7910/DVN/A5KILM) and can be accessed on request from the KEMRI-Wellcome Trust Research Programme Data Governance Committee ([dgc@kemri-wellcome.org](mailto:dgc@kemri-wellcome.org)).

**Funding:** This work was supported by the Wellcome Trust through Senior Research Fellowships (grant number 084226 to JAR) and (grant numbers 091758 and 202800 to TNW), through core support to the KEMRI-Wellcome Trust Research Programme (grant number 203077 to TNW) and through a sub-grant from a Wellcome Trust Strategic Award (grant number 084538 to DHO). The work was partially funded by the European Community's Seventh Framework Programme (FP7/2007-2013) (grant agreement 242095 to TNW) and by the UK Medical Research Council (grant number G0600718 to TNW). The MalariaGEN Consortium was supported by the Wellcome Trust (grant number 077383 to DPK) and by the Foundation for the National Institutes of Health (grant number 566 to DPK) as part of the Bill & Melinda Gates Grand Challenges in Global Health Initiative. The Resource Centre for Genomic Epidemiology of Malaria was supported by the Wellcome Trust (grant number 090770 to DPK). The Wellcome Trust also provided core awards to the Wellcome Trust Centre for Human Genetics (grant number 090532 to DPK) and to the Wellcome Trust Sanger Institute (grant number 098051 to DPK). This work was also supported by the Medical Research Council (grant number G19/9 to DPK). The funders had no role in study design, collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the paper for publication.

**Competing interests:** The authors have declared that no competing interests exist.

## Author summary

The most common human blood group, ABO, affects susceptibility to multiple diseases including malaria, whereby the non-O blood groups A, B and AB are associated with an increased risk of severe malaria in comparison to blood group O. This may occur because red blood cell (RBC) surface-expressed non-O blood group antigens mediate binding to *P. falciparum*-infected RBCs to form clumps known as rosettes, that occlude microvasculature circulation and cause severe malaria pathology. Nevertheless, to date, these conclusions have largely been based on ABO blood groups determined by serological antibody typing. Genetic classification into *AO*, *AA*, *BO*, *BB*, *AB* and *OO* offers a finer and more specific classification of ABO blood groups, but associations with severe malaria and rosetting based on this method have not been described previously. In a case-control study of >5000 Kenyan children, we show that the “double dose” non-O genotypes *AA*, *BB* and *AB* are associated with an increased risk to severe malaria compared to the “single dose” non-O genotypes *AO* and *BO*, and that this is most significant for *AB* versus *AO*. In *in vitro* experiments, double dose non-O genotypes formed larger rosettes compared to single dose non-O genotypes, providing a potential explanation for their increased severe malaria risk.

## Introduction

The ABO blood group was the first human blood group system to be discovered, and has since been widely studied [1]. Three red blood cell (RBC) expressed carbohydrate antigens characterise the ABO system; the A and B antigens are the products of the enzymatic addition of N-acetyl-D-galactosamine (GalNAc) or D-galactose (Gal), respectively, to a precursor H antigen, while an inactive glycosyltransferase fails to add any sugar residues to the H antigen giving rise to blood group O [2]. The resultant A, B, AB and O blood group phenotypes have been associated with numerous diseases [3], most recently including COVID-19 [4], and there is strong evidence to support their role in severe malaria [5]. Blood group O has a high frequency in malaria-endemic regions [6], and has been associated with protection from severe malaria in numerous studies [7–15]. Both observations are consistent with a malaria-selective pressure for blood group O. Additionally, the A and B antigens interact with molecules on the surface of *Plasmodium falciparum* infected red blood cells (iRBCs), such as *P. falciparum* erythrocyte membrane protein 1 (PfEMP1), mediating iRBC binding to uninfected RBCs to form clusters called rosettes [16–20]. Other *P. falciparum* iRBC surface expressed parasite ligands implicated in rosetting include the repetitive interspersed family proteins (RIFIN) interacting with blood group A [19] and the sub-telomeric variant open reading frame (STEVOR) proteins [21]. *P. falciparum* isolates vary in their propensity to form rosettes, high levels of rosetting contributing to impaired microvascular blood flow, and severe malaria [22–24]. Rosetting iRBCs show a “preference” for uninfected A or B RBCs, and form larger, more stable rosettes than with O RBCs [16–19,25–27]. The protection against severe malaria associated with blood group O may be due to reduced rosetting, and hence reduced microvascular obstruction and pathology [7,16,25,28–30].

Previous studies linking ABO blood group to malaria susceptibility and rosetting have either used serological RBC agglutination assays to determine ABO blood group phenotype (A, B, AB, O), or single nucleotide polymorphisms (SNPs) at the *ABO* gene to derive *ABO* genotype (*OO*, *AO*, *AA*, *BO*, *BB*, *AB*), which have then been used to infer ABO phenotypes. While multiple polymorphisms underlie the genetic basis of the ABO system [31,32], most are

rare, and two SNPs rs8176719 and rs8176746 are considered sufficient (>90% accuracy) to infer ABO phenotype [8–15,33,34]. However, the concordance between ABO genotype and ABO phenotype has not been reported in previous population studies of malaria susceptibility, most of which have been conducted in sub-Saharan Africa.

Similarly, few studies have been conducted which have examined the association between ABO genotype (rather than phenotype) and malaria susceptibility, or potential protective mechanisms such as their impacts on rosetting. Prior work shows a gene dosage effect between ABO genotype and the number of ABH antigens on RBCs. For example, AA and BB homozygotes have substantially higher levels of A and B antigens on RBCs than AO and BO heterozygotes respectively [35,36], while AB heterozygotes have antigen levels that are more similar to those found in AA/BB homozygotes [35–39]. The level of A antigen displayed on the RBC surface has been shown to have an impact on rosetting. For example, both rosetting and PfEMP1-binding are substantially reduced in RBCs of the A<sub>2</sub> blood group phenotype, in which fewer A antigen sites are displayed per RBC than cells of the common A<sub>1</sub> phenotype [16,17,40]. However, to the best of our knowledge, whether RBCs from AO and BO genotypes differ in their rosette-forming ability compared to RBCs from AA/BB/AB genotypes with higher levels of A and B antigens has not yet been tested.

Here, we used a case-control study conducted in East Africa to investigate whether specific ABO genotypes are associated with differing levels of susceptibility to severe childhood malaria. In addition, we examined the concordance between ABO genotype and phenotype. We also investigated whether ABO genotypes are associated with risk of uncomplicated malaria or asymptomatic infection in a longitudinal cohort and cross-sectional study, respectively. Finally, through *in vitro* studies, we investigated whether ABO genotype influences either *P. falciparum* rosetting or other parasite adhesion-related phenomena including binding to endothelial receptors and the display of PfEMP1 on the iRBC surface [41]. We hypothesised that individuals with two non-O alleles (AA/BB/AB) might have a greater risk of severe malaria than non-O heterozygotes (AO/BO), due to the former having increased levels of A or B antigens on their RBCs, enabling iRBCs to form larger, more stable rosettes that cause greater microvascular obstruction and pathology.

## Methods

### Ethics and approval and consent to participate

Individual written informed consent was obtained from the parents or guardians of all study participants. All study protocols were approved by the Kenya Medical Research Institute (KEMRI) National Ethical Review Committee (case control study: SCC1192; cohort study: SCC3149). RBCs and sera from Scottish blood donors were obtained following informed consent, with approval from the Scottish National Blood Transfusion Service Committee for the Governance of Blood and Tissue Samples for Nontherapeutic Use (reference SNBTS 12~35).

### Kilifi study area

All epidemiological and clinical studies were conducted in Kilifi County on the coast of Kenya [42]. At the time the studies were conducted, malaria transmission followed a seasonal pattern determined by annual long and short rainy seasons [43].

### Kilifi case-control study

This study has been described in detail elsewhere [14,44,45]. 2245 children aged <14 years who presented to Kilifi County Hospital (KCH) with features of severe malaria were recruited

as cases between January 2001 and January 2008. Severe malaria was classified as the presence of a blood film positive for *P. falciparum* accompanied by any of the following complications: cerebral malaria (CM, a Blantyre Coma Score of <3), severe malarial anaemia (SMA, a haemoglobin concentration of <5g/dl) or respiratory distress (RD, abnormally deep breathing) [46]. In a recent modelling study based on white blood cell and platelet counts in the same cohort of children, it was shown that malaria was probably not the primary cause for the severe disease seen in approximately one third (842 out of 2245) of the “severe malaria” cases [47]. For this reason, these cases were dropped from the current analysis, leaving 1403 cases for inclusion in the current study. Controls (n = 3949) were healthy children who were born within the study area between August 2006 and September 2010 and who were recruited at 3–12 months of age into a genetics cohort study [48]. Therefore, controls were matched to cases by location but differed from cases in age-structure. While not typical of classical case-control design, cord blood or infant samples have been widely used as controls in previous genetic association studies conducted across sub-Saharan Africa [12,13,49], because this provides the most feasible way of collecting large sample numbers in resource-limited settings. Data on ABO blood group (inferred from genotype data) and severe malaria risk from this study have been published previously [14].

### Kilifi longitudinal cohort study

The Kilifi longitudinal cohort study, described in detail elsewhere [50], was established to investigate the immuno-epidemiology of uncomplicated malaria and other common childhood diseases in an area approximately 15 km to the north of KCH [51,52]. Between August 1998 and August 2001, children aged <10 years were recruited into the cohort, including children born from study households during the study period. Cohort members were followed up actively for clinical events on a weekly basis. In addition, members were passively followed for inter-current illnesses at a dedicated clinic at KCH. Finally, the cohort was also monitored for the prevalence of asymptomatic *P. falciparum* carriage through four cross-sectional surveys carried out in March, July and October 2000 and June 2001. Exclusion criteria included death, migration from the study area for more than 2 months and consent withdrawal. Uncomplicated malaria in this cohort was defined as fever (axillary temperature of >37.5°C) with *P. falciparum* infection at any density, in the absence of any signs of severity [53].

### ABO phenotyping and genotyping

Serological typing for ABO blood group phenotypes was carried out by slide haemagglutination assays using anti-A and anti-B monoclonal antibodies (Alba Bioscience, Edinburgh, UK). For genotyping, DNA was extracted from fresh or frozen whole blood samples using either an ABI PRISM 6100 Nucleic acid prep station (Applied Biosystems, Foster City, CA, USA) or QIAamp DNA Blood Mini Kits (Qiagen, West Sussex, United Kingdom) respectively. ABO genotyping was carried out by assessing SNPs rs8176719 and rs8176746, using the SEQUENOM iPLEX Gold (Sequenom) multiplex system following DNA amplification by whole genome amplification, as described previously [8]. rs8176719 in exon 6 of the *ABO* gene on chromosome 9 encodes the 261G deletion giving rise to the *O* allele [31]. rs8176746 in exon 7 of the *ABO* gene encodes C796A which distinguishes A and B alleles [31]. The two SNPs were used to designate ABO genotypes and infer blood groups as described previously in this population [8] and as summarized in Table 1. The common *O* deletion (D) arose on the background of the A allele (C). Therefore, double heterozygotes GD X AC are assumed to have the haplotype GA and DC, giving rise to the *BO* genotype, rather than haplotype GC and DA that gives rise to the *AO* genotype (Table 1). Genotyping for rs334 on *HBB*, which detects the HbS

Table 1. ABO genotype and phenotype frequencies in the case-control study.

rs8176719 X rs8176746 haplotype <sup>§</sup>	Inferred ABO genotype	Cases N (%)	Controls N (%)	ABO serological phenotype <sup>#</sup>	Controls N (%)
DD X CC	OO	605 (43.3)	2030 (52.5)	O	1540 (55.8)
DD X AA	OO	3 (0.2)	1 (0.0)		
DD X AC	OO	14 (1.0)	87 (2.3)		
GD X CC	AO	306 (21.9)	810 (21.0)	A	637 (23.1)
GG X CC	AA	37 (2.7)	83 (2.1)		
GD X AA	BO	13 (0.9)	20 (0.5)	B	503 (18.2)
GD*X AC	BO	324 (23.2)	663 (17.2)		
GG X AA	BB	34 (2.4)	55 (1.4)		
GG X AC	AB	61 (4.4)	115 (3.0)	AB	81 (2.9)

<sup>§</sup>ABO blood group genotypes were determined using two SNPs at the ABO locus; rs8176719 in exon 6 that encodes the 261G deletion giving rise to blood group O with the rs8176719 alleles represented as 261G (G) and 261delG (D); rs8176746 in exon 7 which encodes C796A and distinguishes A and B alleles. Genotyping at both SNPs was successful in 99.6% (1397/1403) severe malaria cases and 97.8% (3864/3949) community controls. 1 severe malaria case and 8 controls had missing genotype data for the rs8176746 SNP but were homozygous for the 261G deletion in exon 6 and were therefore denoted as OO genotype.

\* The common O deletion (D) arose on the background of the A allele (C). Therefore, double heterozygotes GD X AC are assumed to have the haplotype GA and DC, giving rise to the BO genotype, rather than haplotype GC and DA that gives rise to the AO genotype. This assumption is supported by the data shown here, with only 4/5261 children being homozygous for the D deletion on the background of the B allele (AA).

#ABO blood group serological phenotype was determined using standard haemagglutination tests on a sub-group of 2761 (70%) of the community controls. ABO phenotyping was not included as part of the original study design and was only added after the study began, so some controls were not phenotyped.

<https://doi.org/10.1371/journal.pgen.1010910.t001>

mutation that results in sickle cell trait (HbAS) or sickle cell anaemia (HbSS), and for the 3.7Kb  $\alpha$ -globin deletion at the *HBA* locus, which gives rise to the common African variant of  $\alpha^+$ thalassaemia, was conducted by PCR as described elsewhere [54,55]. Compatibility with Hardy-Weinberg Equilibrium (HWE) predictions was determined for ABO genotype SNPs in control samples [12]. SNPs displaying large departures from HWE among controls ( $p < 0.05$ ) can reflect underlying data problems such as genotyping errors or sample bias and should generally be excluded from use in association analyses [56]. In the current study, we found no significant departures from HWE with regard to ABO SNPs among controls ( $\chi^2 = 0.78$ ,  $p = 0.677$ ), and as such, all SNPs were included in our analysis.

## Data analysis for epidemiological studies

Agreement between ABO blood group genotype and serological phenotype was tested using Cohen's Kappa statistic, for which scores of 1 and 0 signify complete agreement and no agreement, respectively.

The Pearson's  $\chi^2$  or Fisher's exact tests were used to test for differences in the distribution of ABO genotypes between severe malaria (including its various clinical sub-types of CM, SMA, RD and mortality) and community controls or across groups in different categorical variables including gender, ethnic group and HbS and  $\alpha^+$ thalassaemia genotypes. We tested for differences in age across ABO genotypes by use of the Kruskal Wallis test.

Odds ratios (ORs) (with 95% confidence intervals, CIs) for severe malaria and its various clinical sub-types were determined by comparison of genotype frequencies among cases and controls, using a fixed-effects logistic-regression model. We conducted both a univariate and multivariate analysis with adjustments for self-reported ethnicity, gender,  $\alpha^+$ thalassaemia and HbAS. The OO genotype was taken as the reference group to which the other blood group genotypes (AO, AA, AB, BO, BB) were compared both individually and as 'non-O' genotypes combined. To test the hypothesis that double dose non-O genotypes (AA, AB, BB) are

associated with a higher risk of severe malaria than single dose non-O genotypes (*AO*, *BO*), ORs between single and double dose non-O genotypes from the logistic regression analysis above were compared using the Wald test. As an alternative approach, logistic regression analysis was carried out as described above, but instead comparing the ORs of severe malaria for double dose genotypes *AA* and *AB* to single dose *AO* as the reference genotype, and similarly comparing *BB* and *AB* to *BO* as the reference genotype.

In the longitudinal cohort study, the impact of *ABO* genotype on the incidence of uncomplicated malaria was investigated using a random effects Poisson regression model with the reference *OO* genotype compared to all other *ABO* genotypes assuming a genotypic model of inheritance, or to non-O genotypes combined in a recessive model of inheritance using the rs8176719 SNP. Incidence Rate Ratios (IRR) were generated from both a univariate model and a multivariate model which were both adjusted for age, season, ethnic group, and HbS and  $\alpha^+$ thalassaemia genotypes. All analyses accounted for within-person clustering of events. For the cross-sectional survey, ORs investigating the impact of *ABO* genotypes on the prevalence of asymptomatic parasitaemia were generated by use of logistic regression analysis. We conducted both a univariate analysis and multivariate analysis with adjustment for confounding by age, season, ethnic group and HbS genotype. The analysis also accounted for clustering of asymptomatic parasitaemia events within individuals.

In the epidemiological analyses, adjustments for multiple testing were not performed; instead, all adjusted ORs, confidence intervals and *p* values have been clearly reported and it is emphasized that no single study is conclusive and additional studies are needed to determine if results are replicable. This approach has been suggested previously for epidemiological data, to avoid potentially important findings being discarded (type II error) due to the stringency of multiple comparison adjustments [57–59].

## Red blood cells

All *in vitro* assays were carried out using malaria negative RBC samples that were collected and processed during May 2009 and May 2010, as described in detail previously [41], as part of the Kilifi longitudinal cohort study, [51,52]. Briefly, whole blood samples were collected into heparinized tubes with plasma aspirated and removed following centrifugation, and white blood cells removed by density centrifugation through Lymphoprep (Fresenius Kabi Norge AS for Axis-Shield PoC AS, Oslo, Norway). Purified RBC pellets were washed and either stored at 4°C and used within 4 days for cytoadhesion assays or cryopreserved in glycerolyte and thawed by standard methods [60, 61] before use for rosetting and PfEMP1 expression assays.

## Parasites and parasite culture

Rosetting assays were carried out with the *P. falciparum* clone IT/R29 [62–66] expressing the ITvar9 PfEMP1 variant that binds to RBCs to form rosettes [62–67]. The ItG *P. falciparum* line used for the *in vitro* static adhesion assays binds to both ICAM-1 and CD36 endothelial receptors and expresses the ITvar16 PfEMP1 variant [62,63]. IT/R29 and ItG are clones derived from the Brazilian IT4/25/5 parasite strain following selection for rosetting (IT/R29) or ICAM-1 binding (ItG) [64]. Due to antigenic switching, both adhesion phenotypes are gradually lost in long-term parasite culture. Therefore, frozen stocks of ItG previously selected for ICAM-1 binding were thawed and used within three weeks [68] while IT/R29 was maintained at a baseline rosetting frequency of >50% by repeated selection using gelatin flotation or density centrifugation on 60% Percoll (Sigma) as previously described [69].

All parasites were maintained using standard culture methods [61] in blood group O + human RBCs. Prior to conducting the *in vitro* experiments, mature pigmented-trophozoite

stage iRBCs were purified to >90% parasitaemia from uninfected and ring-stage iRBCs by magnetic-activated cell sorting (MACS) [70]. The purified iRBCs were then used to invade donor RBCs of different ABO genotypes, in duplicate flasks or duplicate wells in 96-well flat-bottomed plates, at a starting parasitaemia of 1.5% for ItG and 3% for IT/R29 and cultured for 24–48 hours to the mature pigmented-trophozoite stage [41]. RBCs from a local control OO donor were included in all experiments to adjust for day-to-day variation in the assays.

### Rosetting assays

Rosetting was assessed as described previously [41,61]. Briefly, a wet preparation of IT/R29 culture suspension at 2% haematocrit stained with 25µg/ml ethidium-bromide was examined with combined UV/bright field using a Leica DM 2000 fluorescence microscope (x40 objective). A rosette was defined as a mature pigmented trophozoite-stage iRBC binding two or more uninfected RBC, and the number of uninfected RBC bound per rosette was counted for at least 30 rosettes to determine mean rosette size for each donor. The frequency of large rosettes is the percentage of the rosettes counted that had >4 uninfected RBCs per rosette. Sample genotypes were masked to avoid observer bias.

### Static adhesion assays

Static adhesion assays were carried out as described in detail previously [41,68]. Briefly, donor RBC samples infected with ItG *P. falciparum* parasites were assessed for binding to purified recombinant proteins CD36 (R & D Systems, UK) and ICAM1-Fc (a gift from Professor Alister Craig, Liverpool School of Tropical Medicine) spotted on bacteriological petri dishes (BD Falcon 351007) at a concentration of 50µg/ml. Each donor sample was tested once in duplicate dishes run on the same day, with triplicate spots of each protein in each dish. For each spot, 6 images of adherent iRBCs were captured across random fields using an inverted microscope (Eclipse TE2000-S, Nikon, x40 magnification), giving 36 images per protein for each donor RBC. Images were processed and analysed using Image SXM software (University of Liverpool, UK) [71] and the results expressed as the mean number of iRBC bound per mm<sup>2</sup> of surface area.

### PfEMP1 expression assays

Assessment of PfEMP1 expression by flow cytometry, including gating strategies, in donor RBCs infected with the IT/R29 *P. falciparum* clone has been described in detail previously [41]. Briefly, ITvar9 PfEMP1 expression was determined by staining the same preparation of IT/R29 donor iRBC samples tested for rosetting above, with rabbit polyclonal total IgG raised against the ITvar9 variant [72]. ITvar9 PfEMP1 expression was defined by both the median fluorescent intensity (MFI) and proportion of iRBC positively staining with anti-ITvar9 IgG.

### Data analysis for *in vitro* experiments

Multivariate regression analysis was used to test the effect of ABO genotype on rosetting, cytoadhesion or PfEMP1 expression. Potential confounding variables including HbS and  $\alpha^+$ thalassaemia genotypes [41], mean corpuscular volume and complement receptor 1 level [73,74] and Knops blood group [41,44] were first examined in univariate analyses. However, the final model only included the confounding variables HbAS and/or  $\alpha^+$ thalassaemia which showed significant associations on univariate analysis ( $p < 0.05$ ) and an interaction term between the two, and improved the overall model fit tested using the log-likelihood ratio test. Experimental day was included as a covariate to account for day-to-day variation when

experiments were conducted over several days. Non-normally distributed CD36 and ICAM-1 binding data were normalized by square root-transformation. The final list of variables adjusted for in each analysis is shown in the footnote under each respective results table. To visualise the data, dot plots were generated showing individual data points for each donor, normalized to the mean of control donor genotype OO cells run on the same day to account for day-to-day variation. Non-O blood group genotypes were compared to the reference OO genotype using a Kruskal Wallis test with Dunn's multiple comparisons. A  $p$  value of  $<0.05$  was considered significant in all analyses. Statistical analyses were performed in Stata v13.1 (Stata-Corp, Texas, USA) or Prism v7.0 (Graphpad Inc, San Diego, California) and graphs were generated using Prism v7.0.

### Blood group preference of the IT/R29 *P. falciparum* clone

RBCs were obtained from 13 Scottish donors (4 donors of group O and A, and 5 for group B) following verbal consent. After the removal of plasma and white cells as described above, RBCs from the 13 donors, and an aliquot of the uninfected group O RBCs in which the parasites were cultured (hereafter known as 'home O') were labelled with 6-carboxyfluorescein diacetate (C-FDA) (150 $\mu$ g/ml in RPMI 1640 medium), at 2% haematocrit for 15 minutes, washed twice with RPMI 1640 and stored at 4°C. Blood group preference assays were carried out as described [16,17,37]. Briefly, IT/R29 parasites in RPMI 1640 at 6–10% parasitaemia and a rosette frequency of  $>60\%$  were stained with 25 $\mu$ g/ml ethidium bromide for 5 minutes with 200 $\mu$ g/ml fucoidan added to disrupt all rosettes [75]. Labelled uninfected RBCs were also resuspended at 2% haematocrit in RPMI 1640 with 200 $\mu$ g/ml fucoidan. Equal volumes of parasite culture and labelled cells were mixed in triplicate, and the percentage labelled cells in the resulting mixtures counted (300 cells). After 3 washes, cells were resuspended in RPMI 1640 with 10% AB serum and incubated for 1 hour at 37°C to allow rosettes to reform. For each replicate two counts were made: (1) the percentage labelled cells in the mix (300 cells, using only those cells not in rosettes) and (2) the percentage labelled cells in rosettes (200 cells, only those within rosettes). Graphs show the difference between the percentage labelled cells in rosettes and in the mix (using the mean of the 2 counts for % labelled cells in the mix, before and after washes). The mean and SEM of the triplicate readings are shown for each RBC donor. For statistical analysis of the differences between blood groups, the triplicate values for each donor were averaged and treated as a single data point, such that  $n = 4$  for groups O and A, and  $n = 5$  for group B. Blood groups were compared using a Kruskal Wallis test with Dunn's multiple comparisons using Prism v7.0 (Graphpad Inc., San Diego, California).

## Results

### ABO genotypes were strongly concordant with ABO phenotypes in Kenyan children

ABO genotype was determined in a case-control study on susceptibility to severe malaria involving  $>5000$  Kenyan children, while ABO blood group phenotypes were assessed on a sub-group of 2761 control children. O was the most common blood group being found in 55.8% of controls, followed by A (23.1%) and B (18.2%), with AB being relatively rare (2.9%) (Table 1). In terms of genotype, OO was the most common (54.8% of controls), followed by AO (21.0%) and BO (17.7%). The AA (2.1%), BB (1.4%) and AB (3.0%) genotypes were rare (Table 1). The overall agreement between genotype and phenotype was 97.1% (Kappa score, 0.95;  $p < 0.0001$ ), giving confidence that studies using ABO genotype to infer ABO blood group phenotype are based on solid assumptions. The highest agreement was seen for the OO



Table 2. ABO genotype-phenotype agreement<sup>§</sup>.

ABO phenotype	ABO genotype					
	OO N (%)	AO N (%)	AA N (%)	BO N (%)	BB N (%)	AB N (%)
O	<b>1453 (99.3)</b>	25 (4.3)	1 (2.0)	13 (2.8)	3 (7.3)	0 (0.0)
A	4 (0.3)	<b>549 (94.6)</b>	<b>54 (98.0)</b>	17 (3.6)	0 (0.0)	1 (1.4)
B	5 (0.3)	5 (0.9)	0 (0.0)	<b>442 (93.4)</b>	<b>38 (92.7)</b>	2 (2.7)
AB	1 (0.1)	1 (0.2)	0 (0.0)	1 (0.2)	0 (0.0)	<b>71 (95.9)</b>

<sup>§</sup>Agreement between ABO blood group phenotype and ABO genotype was determined for 2686 community control samples that were successfully typed by both methods. The expected genotype-phenotype combinations are highlighted in bold. Overall concordance using Cohen's Kappa statistic was 0.95,  $p < 0.0001$  (a score of 1 corresponds to complete agreement, while 0 corresponds to no agreement).

<https://doi.org/10.1371/journal.pgen.1010910.t002>

genotype, with 99.3% of OO samples being phenotyped as blood group O (Table 2). The blood group A- and AB-encoding genotypes (AO, AA, AB) showed >94% genotype-phenotype concordance. The blood group B encoding genotypes (BO and BB) showed the lowest concordance at 93.4% and 92.7% respectively, with most of the discordant samples being typed as blood group O or A by serology (Table 2).

### The BB and AB genotypes were associated with the highest odds ratios for severe malaria in the case-control study

We next examined the relationship between ABO genotype and susceptibility to severe malaria in the case-control study. Associations between ABO blood group and severe malaria for this full dataset, which also included cases who we have subsequently shown to have a low probability of severe malaria, have been reported previously [14]. However, our current analysis differs by using a more precise case-definition of severe malaria [47], and by focussing on differences between specific non-O genotypes, which were not analysed in the previous study [14]. The general demographic characteristics of the study participants are presented in Table 3. Cases and controls differed in ethnic composition; hence, this variable was included in subsequent analyses. Cases and controls also differed in age, which is a consequence of

Table 3. General characteristics for the Kenyan case-control study.

	Controls	Cases	p value
Kenya	n = 3949	n = 1403 (all severe malaria)	
Gender			
Males	1992 (50.4%)	717 (51.1%)	
Females	1957 (49.6%)	686 (48.9%)	0.670
Ethnicity			
Giriama	1836 (46.5%)	842 (60.0%)	
Chonyi	1408 (35.7%)	317 (22.6%)	
Kauma	450 (11.4%)	94 (6.7%)	
Others	255 (6.5%)	150 (10.7%)	<0.001
Age in months*	6 (5–8)	29 (17–44)	<0.001
Median (IQR)			

Comparisons between cases and controls were performed using the Pearson's Chi square test for gender and ethnic group while the Kruskal Wallis test was used to test for differences in age (as a continuous variable). IQR, interquartile range.

<https://doi.org/10.1371/journal.pgen.1010910.t003>

study design, as described in the methods section. ABO genotype distributions in relation to the variables included in this study are shown in [S1 Table](#). A significantly higher proportion of the controls had the OO genotype compared to the severe malaria cases ([S1 Table](#)). There were minor differences in ABO genotype distribution in relation to gender in controls, which was unexpected and may be a chance finding ([S1 Table](#)). Parasite density in the severe malaria cases did not vary significantly across the different ABO genotypes ([S2 Table](#)).

We tested for associations between ABO genotype and severe malaria, including the specific severe malaria syndromes cerebral malaria (CM), severe malarial anaemia (SMA) and respiratory distress (RD), and malaria-specific mortality using a logistic regression model both with, and without, adjustment for the confounders HbS,  $\alpha^+$ thalassaemia, gender, and ethnicity. When grouped together, the non-O genotypes were associated with a 49% greater risk of all severe malaria (adjusted ORs (aOR) 1.49; 95% CI 1.31–1.70;  $p < 0.001$ ), with similar values for each of the clinical sub-phenotypes individually ([Table 4](#)). When considered separately, the BB and AB genotypes were associated with the highest risks of severe malaria, 108% and 93% greater risk respectively, compared to OO genotype (BB aOR 2.08; 95% CI 1.29–3.37;  $p = 0.003$  and AB aOR 1.93; 95% CI 1.37–2.72;  $p < 0.001$ ), and were also associated with the highest risks for the specific severe malaria syndromes of CM and RD (BB) and SMA (AB) ([Table 4](#)).

To examine the hypothesis that RBC A/B antigen levels affect malaria susceptibility, we used the Wald test to analyse differences in ORs between single (AO, BO) and double dose (AA, AB, BB) non-O genotypes generated by logistic regression analysis above using the OO genotype as the reference group. When compared to OO genotype, AA and AB were associated with a 46% (aOR 1.46; 95% CI 1.29–3.37;  $p = 0.003$ ) and 93% greater risk of severe malaria overall respectively compared to 27% greater risk seen with AO. Similarly, BB (aOR 2.08) and AB (aOR 1.93) were associated with higher odds for all severe malaria than that seen with BO (aOR 1.65). However, only the AB vs AO comparison reached statistical significance ( $p = 0.020$ , [Table 5](#)). Similarly, for the specific severe malaria syndromes, double dose A and/or B genotypes were associated with higher ORs than single dose genotypes in many cases but were not statistically significant ([S3 Table](#)). As an alternative approach to testing our hypothesis, we carried out logistic regression analysis to directly compare the ORs of severe malaria for double dose genotypes AA and AB blood groups to single dose AO as reference and similarly compared BB and AB to BO as reference. Mirroring the Wald test results, double dose non-O genotypes were associated with higher ORs when compared to single dose AO or BO genotypes, but only the AB vs AO comparison was statistically significant ([S4 Table](#)). Overall, the data show patterns that are consistent with the hypothesis, but do not allow us to reject the null hypothesis.

### **AA/AB RBCs form larger rosettes than OO RBCs with a blood group A-preferring *P. falciparum* clone**

To determine whether host RBC ABO genotype influences *P. falciparum* rosetting, we examined rosette size following parasite invasion into RBCs from 60 donors (OO = 23, AO = 18, BO = 9, AA = 2, BB = 1, AB = 7) using the *P. falciparum* clone IT/R29 [64]. Preliminary experiments confirmed a strong blood group A-preference in this parasite line, with a lesser preference for group B RBCs ([S1 Fig](#)) [19,26]. Following parasite invasion and maturation in RBCs from the 60 ABO genotyped donors, the double dose genotype RBCs (AA, BB, AB) formed significantly larger rosettes and showed a higher proportion of large rosettes compared to single dose (AO, BO) and OO genotype RBCs ([Fig 1](#)). In contrast, the single dose AO and BO genotype RBCs did not differ from OO genotype RBCs in terms of rosette size or the proportion of

Table 4. Case-control analysis of the association between ABO genotype and severe malaria syndromes.

Case Phenotype	No. Cases/controls	ABO genotype	Crude				Adjusted <sup>†</sup>			
			OR	LCI	UCI	p value	OR	LCI	UCI	p value
All SM	623/2126	OO	1				1			Reference
	306/810	AO	1.29	1.10	1.51	0.002	1.27	1.07	1.50	0.006
	37/83	AA	1.52	1.02	2.26	0.039	1.46	0.95	2.22	0.082
	61/115	AB	1.81	1.31	2.50	< 0.001	1.93	1.37	2.72	<0.001
	337/683	BO	1.68	1.44	1.97	< 0.001	1.65	1.40	1.95	<0.001
	34/55	BB	2.11	1.36	3.27	0.001	2.08	1.29	3.37	0.003
	775/1746	Non-O	1.52	1.34	1.71	< 0.001	1.49	1.31	1.70	<0.001
All CM	326/2126	OO	1				1			Reference
	166/810	AO	1.34	1.09	1.64	0.005	1.29	1.05	1.60	0.018
	22/83	AA	1.73	1.07	2.81	0.027	1.60	0.96	2.67	0.070
	26/115	AB	1.47	0.95	2.29	0.085	1.47	0.93	2.34	0.101
	160/683	BO	1.53	1.24	1.88	< 0.001	1.45	1.17	1.80	0.001
	16/55	BB	1.90	1.07	3.35	0.027	1.90	1.03	3.49	0.039
	390/1746	Non-O	1.46	1.24	1.71	< 0.001	1.40	1.18	1.65	<0.001
All SMA	181/2126	OO	1				1			Reference
	97/810	AO	1.41	1.09	1.82	0.010	1.35	1.03	1.78	0.031
	9/83	AA	1.27	0.63	2.58	0.773	1.18	0.56	2.52	0.662
	19/115	AB	1.94	1.17	3.32	0.011	2.05	1.21	3.45	0.007
	99/683	BO	1.70	1.31	2.21	< 0.001	1.62	1.23	2.12	0.001
	10/55	BB	2.14	1.07	4.26	0.031	1.71	0.75	3.89	0.204
	234/1746	Non-O	1.57	1.28	1.93	< 0.001	1.50	1.21	1.86	<0.001
All RD*	181/2126	OO	1				1			Reference
	101/810	AO	1.47	1.13	1.89	0.004	1.41	1.08	1.83	0.012
	13/83	AA	1.84	1.01	3.37	0.048	1.68	0.89	3.17	0.113
	12/115	AB	1.23	0.66	2.26	0.516	1.25	0.67	2.33	0.489
	99/683	BO	1.70	1.31	2.21	< 0.001	1.63	1.25	2.13	<0.001
	11/55	BB	2.35	1.21	4.57	0.012	2.01	0.96	4.21	0.064
	236/1746	Non-O	1.59	1.30	1.95	< 0.001	1.51	1.23	1.87	<0.001
Mortality*	52/2126	OO	1				1			Reference
	33/810	AO	1.67	1.07	2.60	0.024	1.74	1.11	2.73	0.017
	2/83	AA	0.99	0.24	4.11	0.984	1.00	0.24	4.21	0.999
	4/115	AB	1.42	0.51	4.00	0.505	1.50	0.53	4.26	0.450
	23/683	BO	1.38	0.84	2.27	0.209	1.35	0.81	2.25	0.258
	2/55	BB	1.49	0.35	6.26	0.589	1.66	0.39	7.08	0.497
	64/1746	Non-O	1.50	1.03	2.17	0.033	1.53	1.04	2.24	0.029

SM: Severe malaria; CM: cerebral malaria; SMA: severe malaria anaemia; RD: respiratory distress; OR: Odds Ratio; LCI: Lower Confidence Interval (95%); UCI: Upper Confidence Interval; P: P-value using a logistic regression model.

<sup>†</sup>adjusted for HbS,  $\alpha$ -thalassaemia, gender, ethnicity and interaction (HbS and  $\alpha$ -thalassaemia).

\* no interaction term included between HbS and  $\alpha$ -thalassaemia genotype.

<https://doi.org/10.1371/journal.pgen.1010910.t004>

large rosettes (Fig 1). Multivariate regression analysis examining each individual ABO genotype and adjusting for confounding variables showed that only the double dose AA and AB genotype RBCs differed significantly from OO genotype RBCs in terms of mean rosette size and proportion of large rosettes (Table 6 and S2 Fig).

Table 5. A comparison of the odds ratio differences for severe malaria between single dose and double dose non-O genotypes using the Wald test.

Case Phenotype	ABO genotype	No. Cases/Controls	Odds Ratio comparisons	Wald test p value
All SM	AO vs AA	306/810; 37/83	1.27/1.46	0.528
	BO vs BB	337/683; 34/55	1.65/2.08	0.351
	AO vs AB	306/810; 61/115	1.27/1.93	0.020
	BO vs AB	337/683; 61/115	1.65/1.93	0.384

Single dose and double dose non-O genotype odds ratios for severe malaria used in the Wald test comparisons were generated following a fixed-effects logistic regression model comparing genotype frequencies between the non-O genotypes to the reference OO genotype with adjustments for self-reported ethnicity, gender,  $\alpha^+$ thalassaemia and HbAS.

<https://doi.org/10.1371/journal.pgen.1010910.t005>

### *P. falciparum* cytoadhesion and PfEMP1 display do not differ between ABO genotypes

Effects on other parasite adhesion-related properties, such as reduced cytoadhesion to microvascular endothelial cells via ICAM-1 and CD36 receptors and reduced display of PfEMP1 on the surface of iRBCs, have been implicated as mechanisms of protection for various human RBC polymorphisms [41,76]. To determine whether ABO genotype might influence malaria




Fig 1. *P. falciparum* IT/R29 rosette size and frequency of large rosettes by ABO genotype. (A) IT/R29 mean rosette size (number of uninfected RBCs per rosette) (B) IT/R29 frequency of large rosettes (more than 4 uninfected RBCs per rosette). Purified IT/R29 infected RBCs (iRBCs) were allowed to invade into RBCs from 60 donors (OO n = 23 white circles, AO n = 18 black squares, BO n = 9 grey squares, AA n = 2 black triangles, BB n = 1 grey triangles, AB n = 7 dark grey triangles) and rosette size and frequency of large rosettes were assessed the next day by fluorescence microscopy. Samples were tested over two consecutive experimental days (day 1 = 30 and day 2 = 30) in duplicates. Horizontal bars represent the median rosette size and median frequency of large rosettes single dose (AO, BO) and double dose (AA, BB, AB) genotypes. The number of donors per genotype are shown in parenthesis. Sample genotype was masked during counting to avoid observer bias. \*\* Double dose non-O genotypes differed from OO in mean rosette size (Kruskal Wallis test with Dunn’s multiple comparisons p = 0.0065) and frequency of large rosettes (Kruskal Wallis test with Dunn’s multiple comparisons p = 0.0068).

<https://doi.org/10.1371/journal.pgen.1010910.g001>

**Table 6. Rosetting of *P. falciparum* clone IT/R29 by ABO genotype.**

IT/R29 rosette size				
N	Genotype	Mean rosette size	95% CI	p value
23	OO	2.89	2.77–3.01	-
18	AO	2.92	2.78–3.05	0.737
2	AA	3.36	2.95–3.78	0.030
9	BO	2.92	2.73–3.11	0.773
1	BB	2.52	1.93–3.11	0.229
7	AB	3.28	3.06–3.50	0.003
37	Non-O	3.00	2.92–3.11	0.157
Frequency of IT/R29 large rosettes				
N	Genotype	% of large rosettes (>4 uninfected RBCs/rosette)	95% CI	p value
23	OO	8.49	5.75–12.22	-
18	AO	9.36	6.27–12.22	0.674
2	AA	20.55	11.20–29.91	0.016
9	BO	8.45	4.09–12.81	0.988
1	BB	1.29	-12.01–14.59	0.296
7	AB	18.23	13.19–23.28	0.001
37	Non-O	11.27	8.89–13.66	0.143

Differences in IT/R29 rosette size or frequency of large rosettes by ABO genotype were tested using multivariate regression analysis with adjustment for confounding by HbAS. 60 RBC donor samples were tested once in duplicate over two successive experimental days (day 1 n = 30 and day 2 n = 30), therefore, experimental day was included as a co-variate to account for day-to-day variation.

<https://doi.org/10.1371/journal.pgen.1010910.t006>

susceptibility via these mechanisms, we conducted *in vitro* experiments examining cytoadhesion to ICAM-1 and CD36 and PfEMP1 display in relation to infected RBC ABO genotype. No genotype-specific differences were seen (S3 and S4 Figs and S5 and S6 Tables).

### ABO genotype is not associated with risk of either uncomplicated malaria or asymptomatic infection

Rosetting is primarily a property of parasite isolates causing severe malaria, and no (or very low level) rosetting is seen in *P. falciparum* isolates collected from patients with uncomplicated malaria [28,77]. If ABO genotype influences malaria susceptibility via a mechanism related to rosette size and microvascular obstruction, we would predict that ABO genotype associations would only be demonstrated in severe disease, and not in mild or asymptomatic infections. We tested this hypothesis using a longitudinal cohort study and cross-sectional surveys carried out in the same geographic area as the case-control study. No significant associations were seen between ABO genotype and either uncomplicated malaria or asymptomatic *P. falciparum* infection (S7–S9 Tables).

### Discussion

Although associations between ABO blood group, *P. falciparum* rosetting and susceptibility to severe malaria are well-established [9–11,16,20,28,78–80], to the best of our knowledge, higher resolution analyses to determine their associations with distinct ABO genotypes have not been conducted. Our results show a significant effect of ABO genotype on rosette size, with double dose AA/AB genotype RBCs forming significantly larger rosettes than OO genotype RBCs with the A-preferring *P. falciparum* line IT/R29. In contrast, single dose AO and BO genotype RBCs

did not differ from OO genotype RBCs in the rosetting assays. Previous work has shown that rosettes in non-O blood are not only larger but are also more stable and more difficult to disrupt with reagents such as heparin, compared to rosettes in group O RBCs, [16,18,19,26,29]. Rosette size and stability are of great potential importance in malaria pathology, because experimental studies show that larger rosettes in A compared to O RBCs are more resistant to disruption under shear stress and therefore cause greater obstruction to capillary-sized channels [27]. Hence, a direct causal link between host ABO genotype, parasite virulence in terms of rosette size, and the primary pathological process of microvascular obstruction in severe malaria is suggested.

Our finding that the ABO gene dose affects rosetting supports our prediction that AA/BB/AB individuals will be at higher risk of severe malaria than AO/BO individuals. In the case-control study we found that for most comparisons, AA/BB/AB individuals had higher ORs for severe malaria and specific severe malaria syndromes than AO and BO individuals, but we could not reject the null hypothesis on statistical grounds. Despite recruiting ~1400 severe malaria cases into our study, the frequency of the key AA, BB and AB genotypes in the dataset was low (37, 34 and 61 severe cases respectively) which limited the power of our study. Similarly, the *in vitro* rosetting assays, which used RBCs collected from the same study area as the epidemiological work, were limited by small sample size in the double dose genotypes (AA, AB and BB). Future studies with larger sample sizes in the key double dose genotypes will be needed to confirm our findings.

Our *in vitro* rosetting results support previous suggestions that rosetting is a causal factor in the protective association between ABO blood group and severe malaria [7,16,25,29]. However, alternative protective mechanisms have been suggested for other polymorphisms [41,81]. We examined two of these mechanisms here, iRBC binding to endothelial receptors (ICAM-1 and CD36) and PfEMP1 expression levels on the surface of iRBCs. We found no evidence for an association between ABO genotype and either endothelial receptor binding or PfEMP1 display. However, our study only used a single parasite clone (ItG, expressing the ITvar16 PfEMP1 variant) and two endothelial receptors. Future studies could further explore the role of ABO on cytoadhesion using other *P. falciparum* clones/variants and additional endothelial receptors. The only previous study to examine ABO and cytoadhesion found no effect of ABO serological phenotype on binding to multiple endothelial receptors, with decreased ICAM-1 adhesion in non-O blood groups being the only significant result [82], a finding that is inconsistent with the association between non-O and increased risk of severe malaria. Other protective mechanisms for ABO have also been suggested, including effects on RBC invasion [83,84] and phagocytic clearance of iRBCs [26,85,86]. However, both invasion- and clearance-related mechanisms would be expected to have an impact by lowering parasite burden, yet no consistent effect of ABO blood group on parasite density has been seen across multiple studies (reviewed by [80]), and we found no significant association in our case-control study (S2 Table). Taken together, existing data support a role for reduced *P. falciparum* rosetting in O RBCs and consequent reduced microvascular obstruction, as a key mechanism by which ABO blood group influences the risk of severe malaria.

An additional aim of our study was to investigate the correlation between ABO genotype and blood group phenotype in an African population. We report strong agreement between ABO genotype and phenotype, with only 79/2686 samples (2.9%) being discordant. The strongest concordance was for genotype OO with blood group O (99.3%), and the weakest for genotype BB with blood group B (92.3%). Two American studies using the same SNPs reported a genotype-phenotype concordance of 100% and 92% respectively, although the perfect concordance seen by Risch and colleagues could potentially have been a reflection of their very small sample size (n = 30) [33,34]. Some discrepancies in our study, for example, the 42 samples

genotyped as AO, AA, BO and BB but serologically typed as blood group O, could be due to weak A and B subgroups that reduce A and B antigen density on the RBC surface [87–89], which might have resulted in samples being typed as O in standard agglutination assays [90–93]. Another possible source of error might have resulted from the assumption made in inferring ABO genotype in heterozygotes. 62/79 (78%) of discrepant samples were heterozygous for the O deletional allele (“GD” in Table 1). The double heterozygote combination of GD at rs8176719 and AC at rs8176746 can result in either BO genotype (GA and DC haplotype) or AO genotype from the rare GC and DA haplotype. The O deletion is thought to have arisen on the background of an A allele [2], so all individuals were assigned as BO genotype. However, O deletions arising on a B allele background have been described [94], and could account for some of the discrepancies we observed. Finally, it is also possible that some samples were erroneously typed by serology. We were unable to access fresh RBC samples from the same individuals to repeat the typing.

## Conclusions

In conclusion, our combined epidemiological and laboratory studies support the hypothesis that AO/BO heterozygotes differ from AA/AB/BB individuals in relation to *P. falciparum* rosetting and severe malaria risk. Alternative mechanisms of protection for blood group O and the OO genotype, such as binding to endothelial receptors ICAM-1 and CD36 and effects on PfEMP1 display were not supported by the data. Additional studies examining the effects of ABO genotype, as well as weak A and B blood groups, may give further insights into the complex host-parasite interactions in severe malaria.

## Supporting information

**S1 Table. The general characteristics of children recruited to the case-control study by ABO genotype.**

(PDF)

**S2 Table. *P. falciparum* parasite density by ABO genotype in severe malaria cases.**

(PDF)

**S3 Table. Comparing Odds ratio differences for specific severe malaria syndromes between single dose and double dose non-O genotypes using the Wald test.**

(PDF)

**S4 Table. A comparison of the odds ratio differences for severe malaria between single dose and double dose non-O genotypes using logistic regression with single dose non-O genotypes AO/BO as reference.**

(PDF)

**S5 Table. Cytoadhesion of *P. falciparum* line ItG by ABO genotype.**

(PDF)

**S6 Table. ITvar9 PfEMP1 expression by ABO genotype.**

(PDF)

**S7 Table. General characteristics of the Kilifi longitudinal cohort study by ABO genotype.**

(PDF)

**S8 Table. Incidence rate ratios (IRR) for uncomplicated malaria in Kenya by ABO genotype.**

(PDF)

**S9 Table. Odds ratios (OR) for asymptomatic malaria in Kenya by ABO genotype.**  
(PDF)

**S1 Fig. *P. falciparum* IT/R29 ABO blood group rosetting preference.** ABO blood group preference assay of the IT/R29 parasite clone was assessed using fluorescently-labelled RBC from 13 donors (4 group O, 4 group A and 5 group B). “Home O” indicates the blood group O donor that was used to culture the parasites. The y-axis shows the difference between the percentage of labelled cells found in rosettes, compared to the percentage found in the mix. Experiments were carried out in triplicate, and the mean and SEM are shown for each donor. For statistical analysis, the triplicate values for each donor were averaged and treated as a single data point, such that  $n = 4$  for groups O and A, and  $n = 5$  for group B. The blood groups were compared using a Kruskal Wallis test with Dunn’s multiple comparisons (\*\*  $p < 0.01$ ).  
(TIFF)

**S2 Fig. *P. falciparum* IT/R29 rosette size and frequency of large rosettes by ABO genotype.** (A) IT/R29 mean rosette size (number of uninfected RBCs per rosette) (B) IT/R29 frequency of large rosettes (more than 4 uninfected RBCs per rosette). Purified IT/R29 infected RBCs (iRBCs) were allowed to invade into RBCs from 60 donors ( $OO n = 23$ ,  $AO n = 18$ ,  $BO n = 9$ ,  $AA n = 2$ ,  $BB n = 1$ ,  $AB n = 7$ ) and rosette size and frequency of large rosettes were assessed after one complete life-cycle by fluorescence microscopy. Samples were tested over two consecutive experimental days (day 1 = 30 and day 2 = 30) in duplicates. Horizontal bars represent the median rosette size and median frequency of large rosettes for each genotype. The number of donors per genotype are shown in parenthesis. Sample genotype was masked during counting to avoid observer bias. \*\**AB* differed from *OO* for both mean rosette size and frequency of large rosettes,  $p < 0.01$  Kruskal-Wallis test with Dunn’s multiple comparisons.  
(TIFF)

**S3 Fig. Relative cytoadherence of *P. falciparum* ITg by ABO genotype.** (A) Relative binding to CD36 recombinant protein. (B) Relative binding to ICAM-1 recombinant protein. Purified ITg infected RBCs (iRBCs) were allowed to invade into RBCs from 112 donors ( $OO n = 51$ ,  $AO n = 32$ ,  $BO n = 17$ ,  $AA n = 6$ ,  $BB n = 3$ ,  $AB n = 3$ ) and static adhesion to immobilized recombinant proteins was tested after one complete life-cycle. Samples were tested over seven experimental days (day 1  $n = 13$ , day 2  $n = 8$ , day 3  $n = 12$ , day 4  $n = 1$ , day 5  $n = 55$ , day 6  $n = 15$  and day 7  $n = 8$ ), with each donor being tested once. For each RBC sample, adhesion was tested in two dishes with triplicate protein spots in each dish and the data presented as the mean iRBC bound/ $\text{mm}^2$  for each donor. Because baseline binding using a single donor varies from day to day, the binding data for each sample were normalized to that of the mean binding for the control iRBCs (*OO*) run on the same day (number of reference *OO* genotype samples run each day; day 1  $n = 7$ , day 2  $n = 4$ , day 3  $n = 8$ , day 4  $n = 1$ , day 5  $n = 23$ , day 6  $n = 7$  and day 7  $n = 2$ ). Horizontal bars represent median relative adhesion for each genotype. Number of samples per genotype are shown in parenthesis. A Kruskal-Wallis test gave  $p = 0.310$  for CD36 adhesion and  $p = 0.814$  for ICAM-1 adhesion.  
(TIFF)

**S4 Fig. Relative PfEMP1 expression in *P. falciparum* IT/R29 by ABO genotype.** (A) Relative ITvar9 PfEMP1 expression. (B) Relative ITvar9 positive iRBCs. Purified IT/R29 infected RBCs (iRBCs) were allowed to invade into RBCs from 60 donors ( $OO n = 23$ ,  $AO n = 18$ ,  $BO n = 9$ ,  $AA n = 2$ ,  $BB n = 1$ ,  $AB n = 7$ ) and PfEMP1 expression was assessed after one complete life-cycle by flow cytometry with antibodies specific for the ITvar9 PfEMP1 variant. Samples were tested over two consecutive experimental days (day 1 = 30 and day 2 = 30). Median fluorescent



intensity and proportion of ITvar9 positive iRBC data for all samples were normalized to that of the mean MFI and proportion of ITvar9 positive iRBCs for the control pRBCs (OO) (14 and 9 reference OO genotype samples run on day 1 and 2 respectively) run on the same day. Horizontal bars represent median relative MFI and proportion of ITvar9 positive iRBCs for each genotype. Kruskal-Wallis test  $p = 0.076$  for MFI and  $p = 0.285$  for % positive iRBCs. (TIFF)

## Acknowledgments

We are grateful to all the children who donated samples to this study, and their parents and guardians. We are also grateful to the clinical, field and laboratory staff at the KEMRI-Wellcome Trust Research Programme, including the laboratory team for the Human Genetics Group. We also thank Professor Alister Craig (Liverpool School of Tropical Medicine) for his generous contribution of the ICAM-1-Fc purified recombinant protein.

This paper was published with permission from the Director of the Kenya Medical Research Institute (KEMRI).

## Author Contributions

**Conceptualization:** D. Herbert Opi, Thomas N. Williams, J. Alexandra Rowe.

**Data curation:** Carolyne M. Ndila, Lucy B. Ochola, Gideon Nyutu, Bethseba R. Siddondo, Gavin Band, Kirk A. Rockett.

**Formal analysis:** D. Herbert Opi, Carolyne M. Ndila, Thomas N. Williams, J. Alexandra Rowe.

**Funding acquisition:** Dominic P. Kwiatkowski, Thomas N. Williams, J. Alexandra Rowe.

**Investigation:** D. Herbert Opi, Carolyne M. Ndila, Sophie Uyoga, Alex W. Macharia, Clare Fennell, Gideon Nyutu, John Ojal, Mohammed Shebe, Kennedy O. Awuondo, Neema Mturi, Norbert Peshu, Benjamin Tsofa, Gavin Band, Kathryn Maitland, Dominic P. Kwiatkowski, Kirk A. Rockett, Thomas N. Williams, J. Alexandra Rowe.

**Methodology:** D. Herbert Opi.

**Supervision:** Thomas N. Williams, J. Alexandra Rowe.

**Validation:** Thomas N. Williams, J. Alexandra Rowe.

**Writing – original draft:** D. Herbert Opi, Thomas N. Williams, J. Alexandra Rowe.

**Writing – review & editing:** D. Herbert Opi, Carolyne M. Ndila, Sophie Uyoga, Alex W. Macharia, Clare Fennell, Gideon Nyutu, John Ojal, Mohammed Shebe, Kennedy O. Awuondo, Neema Mturi, Norbert Peshu, Benjamin Tsofa, Gavin Band, Kathryn Maitland, Dominic P. Kwiatkowski, Kirk A. Rockett, Thomas N. Williams, J. Alexandra Rowe.

## References

1. Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. *Immunohematology*. 2009; 25(2):48–59. Epub 2009/11/26. PMID: [19927620](https://pubmed.ncbi.nlm.nih.gov/19927620/).
2. Daniels G. The molecular genetics of blood group polymorphism. *Transpl Immunol*. 2005; 14(3–4):143–53. Epub 2005/06/29. <https://doi.org/10.1016/j.trim.2005.03.003> [pii] PMID: [15982556](https://pubmed.ncbi.nlm.nih.gov/15982556/).
3. Yamamoto F, Cid E, Yamamoto M, Blancher A. ABO research in the modern era of genomics. *Transfus Med Rev*. 2012; 26(2):103–18. Epub 2011/09/29. <https://doi.org/10.1016/j.tmr.2011.08.002> PMID: [21945157](https://pubmed.ncbi.nlm.nih.gov/21945157/).

4. Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med.* 2020; 383(16):1522–34. Epub 2020/06/20. <https://doi.org/10.1056/NEJMoa2020283> PMID: 32558485; PubMed Central PMCID: PMC7315890.
5. Rowe JA, Opi DH, Williams TN. Blood groups and malaria: fresh insights into pathogenesis and identification of targets for intervention. *Curr Opin Hematol.* 2009; 16(6):480–7. Epub 2009/10/09. <https://doi.org/10.1097/MOH.0b013e3283313de0> PMID: 19812491.
6. Cserti CM, Dzik WH. The ABO blood group system and *Plasmodium falciparum* malaria. *Blood.* 2007; 110(7):2250–8. Epub 2007/05/16. <https://doi.org/10.1182/blood-2007-03-077602> PMID: 17502454.
7. Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Kone A, et al. Blood group O protects against severe *Plasmodium falciparum* malaria through the mechanism of reduced rosetting. *Proc Natl Acad Sci U S A.* 2007; 104(44):17471–6. Epub 2007/10/26. <https://doi.org/10.1073/pnas.0705390104> PMID: 17959777.
8. Fry AE, Griffiths MJ, Auburn S, Diakite M, Forton JT, Green A, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe *Plasmodium falciparum* malaria. *Hum Mol Genet.* 2008; 17(4):567–76. Epub 2007/11/16. <https://doi.org/10.1093/hmg/ddm331> [pii] PMID: 18003641.
9. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, Clark TG, et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. *Nat Genet.* 2009; 41(6):657–65. Epub 2009/05/26. ng.388 [pii] <https://doi.org/10.1038/ng.388> PMID: 19465909; PubMed Central PMCID: PMC2889040.
10. Timmann C, Thye T, Vens M, Evans J, May J, Ehmen C, et al. Genome-wide association study indicates two novel resistance loci for severe malaria. *Nature.* 2012; 489(7416):443–6. Epub 2012/08/17. nature11334 [pii] <https://doi.org/10.1038/nature11334> PMID: 22895189.
11. Toure O, Konate S, Sissoko S, Niangaly A, Barry A, Sall AH, et al. Candidate polymorphisms and severe malaria in a Malian population. *PLoS One.* 2012; 7(9):e43987. Epub 2012/09/08. <https://doi.org/10.1371/journal.pone.0043987> PONE-D-12-10698 [pii]. PMID: 22957039; PubMed Central PMCID: PMC3434208.
12. The Malaria Genomic Epidemiology Network. Reappraisal of known malaria resistance loci in a large multicenter study. *Nat Genet.* 2014; 46(11):1197–204. Epub 2014/09/30. <https://doi.org/10.1038/ng.3107> PMID: 25261933.
13. Band G, Le QS, Jostins L, Pirinen M, Kivinen K, Jallow M, et al. Imputation-based meta-analysis of severe malaria in three African populations. *PLoS Genet.* 2013; 9(5):e1003509. Epub 2013/05/30. <https://doi.org/10.1371/journal.pgen.1003509> PMID: 23717212; PubMed Central PMCID: PMC3662650.
14. Ndila CM, Uyoga S, Macharia AW, Nyutu G, Peshu N, Ojal J, et al. Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. *The Lancet Haematology.* 2018; 5(8):e333–e45. Epub 2018/07/24. [https://doi.org/10.1016/S2352-3026\(18\)30107-8](https://doi.org/10.1016/S2352-3026(18)30107-8) PMID: 30033078; PubMed Central PMCID: PMC6069675.
15. Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. *Nat Commun.* 2019; 10(1):5732. Epub 2019/12/18. <https://doi.org/10.1038/s41467-019-13480-z> PMID: 31844061; PubMed Central PMCID: PMC6914791.
16. Carlson J, Wahlgren M. *Plasmodium falciparum* erythrocyte rosetting is mediated by promiscuous lectin-like interactions. *J Exp Med.* 1992; 176(5):1311–7. Epub 1992/11/01. <https://doi.org/10.1084/jem.176.5.1311> PMID: 1402677.
17. Vigan-Womas I, Guillotte M, Juillerat A, Hessel A, Raynal B, England P, et al. Structural basis for the ABO blood-group dependence of *Plasmodium falciparum* rosetting. *PLoS Pathog.* 2012; 8(7):e1002781. Epub 2012/07/19. <https://doi.org/10.1371/journal.ppat.1002781> PPATHOGENS-D-11-02831 [pii]. PMID: 22807674; PubMed Central PMCID: PMC3395597.
18. Barragan A, Kremsner PG, Wahlgren M, Carlson J. Blood group A antigen is a coreceptor in *Plasmodium falciparum* rosetting. *Infect Immun.* 2000; 68(5):2971–5. Epub 2000/04/18. <https://doi.org/10.1128/IAI.68.5.2971-2975.2000> PMID: 10768996.
19. Goel S, Palmkvist M, Moll K, Joannin N, Lara P, R RA, et al. RIFINs are adhesins implicated in severe *Plasmodium falciparum* malaria. *Nat Med.* 2015; 21(4):314–7. Epub 2015/03/10. <https://doi.org/10.1038/nm.3812> PMID: 25751816.
20. McQuaid F, Rowe JA. Rosetting revisited: a critical look at the evidence for host erythrocyte receptors in *Plasmodium falciparum* rosetting. *Parasitology.* 2020; 147(1):1–11. Epub 2019/08/29. <https://doi.org/10.1017/S0031182019001288> PMID: 31455446; PubMed Central PMCID: PMC7050047.
21. Niang M, Bei AK, Madhani KG, Pelly S, Dankwa S, Kanjee U, et al. STEVOR is a *Plasmodium falciparum* erythrocyte binding protein that mediates merozoite invasion and rosetting. *Cell Host Microbe.*

- 2014; 16(1):81–93. Epub 2014/07/11. <https://doi.org/10.1016/j.chom.2014.06.004> PMID: 25011110; PubMed Central PMCID: PMC4382205.
22. Kaul DK, Roth EF Jr, Nagel RL, Howard RJ, Handunnetti SM. Rosetting of *Plasmodium falciparum*-infected red blood cells with uninfected red blood cells enhances microvascular obstruction under flow conditions. *Blood*. 1991; 78(3):812–9. Epub 1991/08/11. PMID: 1859893.
  23. Dondorp AM, Ince C, Charunwatthana P, Hanson J, van Kuijen A, Faiz MA, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. *J Infect Dis*. 2008; 197(1):79–84. Epub 2008/01/04. <https://doi.org/10.1086/523762> PMID: 18171289.
  24. Doumbo OK, Thera MA, Kone AK, Raza A, Tempest LJ, Lyke KE, et al. High levels of *Plasmodium falciparum* rosetting in all clinical forms of severe malaria in African children. *Am J Trop Med Hyg*. 2009; 81(6):987–93. Epub 2009/12/10. <https://doi.org/10.4269/ajtmh.2009.09-0406> [pii] PMID: 19996426.
  25. Udomsangpetch R, Todd J, Carlson J, Greenwood BM. The effects of hemoglobin genotype and ABO blood group on the formation of rosettes by *Plasmodium falciparum*-infected red blood cells. *Am J Trop Med Hyg*. 1993; 48(2):149–53. Epub 1993/02/01. <https://doi.org/10.4269/ajtmh.1993.48.149> PMID: 8447516.
  26. Moll K, Palmkvist M, Ch'ng J, Kiwuwa MS, Wahlgren M. Evasion of Immunity to *Plasmodium falciparum*: Rosettes of Blood Group A Impair Recognition of PfEMP1. *PLoS One*. 2015; 10(12):e0145120. Epub 2015/12/30. <https://doi.org/10.1371/journal.pone.0145120> PMID: 26714011; PubMed Central PMCID: PMC4694710.
  27. Jötten AM, Moll K, Wahlgren M, Wixforth A, Westerhausen C. Blood group and size dependent stability of *P. falciparum* infected red blood cell aggregates in capillaries. *Biomicrofluidics*. 2020; 14(2):024104. Epub 2020/03/25. <https://doi.org/10.1063/1.5125038> PMID: 32206159; PubMed Central PMCID: PMC7083652.
  28. Rowe A, Obeiro J, Newbold CI, Marsh K. *Plasmodium falciparum* rosetting is associated with malaria severity in Kenya. *Infect Immun*. 1995; 63(6):2323–6. Epub 1995/06/01. <https://doi.org/10.1128/iai.63.6.2323-2326.1995> PMID: 7768616.
  29. Carlson J, Nash GB, Gabutti V, al-Yaman F, Wahlgren M. Natural protection against severe *Plasmodium falciparum* malaria due to impaired rosette formation. *Blood*. 1994; 84(11):3909–14. Epub 1994/12/01. PMID: 7949147.
  30. Chotivanich KT, Udomsangpetch R, Pipitaporn B, Angus B, Suputtamongkol Y, Pukrittayakamee S, et al. Rosetting characteristics of uninfected erythrocytes from healthy individuals and malaria patients. *Ann Trop Med Parasitol*. 1998; 92(1):45–56. Epub 1998/06/06. <https://doi.org/10.1080/00034989860166> PMID: 9614453.
  31. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. *Nature*. 1990; 345(6272):229–33. Epub 1990/05/17. <https://doi.org/10.1038/345229a0> PMID: 2333095.
  32. Yamamoto F, Hakomori S. Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions. *J Biol Chem*. 1990; 265(31):19257–62. Epub 1990/11/05. PMID: 2121736.
  33. Risch HA, Lu L, Wang J, Zhang W, Ni Q, Gao YT, et al. ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. *Am J Epidemiol*. 2013; 177(12):1326–37. Epub 2013/05/09. <https://doi.org/10.1093/aje/kws458> PMID: 23652164; PubMed Central PMCID: PMC3732019.
  34. Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Stepkowski E, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. *Cancer Res*. 2010; 70(3):1015–23. Epub 2010/01/28. <https://doi.org/10.1158/0008-5472.CAN-09-2993> PMID: 20103627; PubMed Central PMCID: PMC2943735.
  35. Sharon R, Duke-Cohan JS, Galili U. Determination of ABO blood group zygosity by an antiglobulin rosetting technique and cell-based enzyme immunoassay. *Vox Sang*. 1986; 50(4):245–9. Epub 1986/01/01. <https://doi.org/10.1111/j.1423-0410.1986.tb04890.x> PMID: 3487882.
  36. Sharon R, Fibach E. Quantitative flow cytometric analysis of ABO red cell antigens. *Cytometry*. 1991; 12(6):545–9. Epub 1991/01/01. <https://doi.org/10.1002/cyto.990120611> PMID: 1764978.
  37. Economidou J, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites. *Vox Sang*. 1967; 12(5):321–8. Epub 1967/05/01. <https://doi.org/10.1111/j.1423-0410.1967.tb03362.x> PMID: 6067900.
  38. Berneman ZN, van Bockstaele DR, Uyttenbroeck WM, Van Zaelen C, Cole-Dergent J, Muylle L, et al. Flow-cytometric analysis of erythrocytic blood group A antigen density profile. *Vox Sang*. 1991; 61(4):265–74. Epub 1991/01/01. <https://doi.org/10.1111/j.1423-0410.1991.tb00958.x> PMID: 1776244.
  39. Hult AK, Olsson ML. Many genetically defined ABO subgroups exhibit characteristic flow cytometric patterns. *Transfusion*. 2010; 50(2):308–23. Epub 2009/10/07. <https://doi.org/10.1111/j.1537-2995.2009.02398.x> PMID: 19804572.

40. Hedberg P, Sirel M, Moll K, Kiwua MS, Hoglund P, Ribacke U, et al. Red blood cell blood group A antigen level affects the ability of heparin and PfEMP1 antibodies to disrupt *Plasmodium falciparum* rosettes. *Malar J*. 2021; 20(1):441. Epub 2021/11/20. <https://doi.org/10.1186/s12936-021-03975-w> PMID: 34794445; PubMed Central PMCID: PMC8600353.
41. Opi DH, Ochola LB, Tendwa M, Siddondo BR, Ocholla H, Fanjo H, et al. Mechanistic Studies of the Negative Epistatic Malaria-protective Interaction Between Sickle Cell Trait and alphas-thalassaemia. *EBio-Medicine*. 2014; 1(1):29–36. Epub 2015/04/22. <https://doi.org/10.1016/j.ebiom.2014.10.006> PMID: 25893206; PubMed Central PMCID: PMC4397954.
42. Scott JA, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). *Int J Epidemiol*. 2012. Epub 2012/05/01. dys062 [pii] <https://doi.org/10.1093/ije/dys062> PMID: 22544844.
43. O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. *Lancet*. 2008; 372(9649):1555–62. Epub 2008/11/06. [https://doi.org/10.1016/S0140-6736\(08\)61655-4](https://doi.org/10.1016/S0140-6736(08)61655-4) [pii] PMID: 18984188; PubMed Central PMCID: PMC2607008.
44. Opi DH, Swann O, Macharia A, Uyoga S, Band G, Ndila CM, et al. Two complement receptor one alleles have opposing associations with cerebral malaria and interact with alpha(+)-thalassaemia. *eLife*. 2018;7. Epub 2018/04/25. <https://doi.org/10.7554/eLife.31579> PMID: 29690995; PubMed Central PMCID: PMC5953541.
45. Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, et al. Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study. *The Lancet Haematology*. 2015; 2(10):e437–44. Epub 2015/12/22. [https://doi.org/10.1016/S2352-3026\(15\)00152-0](https://doi.org/10.1016/S2352-3026(15)00152-0) PMID: 26686045; PubMed Central PMCID: PMC4703047.
46. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, et al. Indicators of life-threatening malaria in African children. *N Engl J Med*. 1995; 332(21):1399–404. Epub 1995/05/25. <https://doi.org/10.1056/NEJM199505253322102> PMID: 7723795.
47. Watson JA, Ndila CM, Uyoga S, Macharia A, Nyutu G, Mohammed S, et al. Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. *eLife*. 2021;10. Epub 2021/07/07. <https://doi.org/10.7554/eLife.69698> PMID: 34225842; PubMed Central PMCID: PMC8315799.
48. Uyoga S, Macharia AW, Mochamah G, Ndila CM, Nyutu G, Makale J, et al. The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study. *Lancet Glob Health*. 2019; 7(10):e1458–e66. Epub 2019/08/28. [https://doi.org/10.1016/S2214-109X\(19\)30328-6](https://doi.org/10.1016/S2214-109X(19)30328-6) PMID: 31451441.
49. Clarke GM, Rockett K, Kivinen K, Hubbart C, Jeffreys AE, Rowlands K, et al. Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia. *eLife*. 2017;6. Epub 2017/01/10. <https://doi.org/10.7554/eLife.15085> PMID: 28067620; PubMed Central PMCID: PMC5222559.
50. Nyakeriga AM, Troye-Blomberg M, Chemtai AK, Marsh K, Williams TN. Malaria and nutritional status in children living on the coast of Kenya. *Am J Clin Nutr*. 2004; 80(6):1604–10. Epub 2004/12/09. <https://doi.org/10.1093/ajcn/80.6.1604> [pii]. PMID: 15585775.
51. Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, Mwacharo JK, et al. The effect of alpha +-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. *PLoS Med*. 2006; 3(5):e158. Epub 2006/04/12. <https://doi.org/10.1371/journal.pmed.0030158> [pii] PMID: 16605300.
52. Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, et al. Sickle cell trait and the risk of *Plasmodium falciparum* malaria and other childhood diseases. *J Infect Dis*. 2005; 192(1):178–86. Epub 2005/06/09. <https://doi.org/10.1086/430744> [pii] PMID: 15942909.
53. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. *J Infect Dis*. 2005; 191(11):1932–9. Epub 2005/05/05. <https://doi.org/10.1086/430006> [pii] PMID: 15871128.
54. Waterfall CM, Cobb BD. Single tube genotyping of sickle cell anaemia using PCR-based SNP analysis. *Nucleic Acids Res*. 2001; 29(23):E119. Epub 2001/12/01. <https://doi.org/10.1093/nar/29.23.e119> PMID: 11726702.
55. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletion determinants of alpha-thalassaemia. *Blood*. 2000; 95(1):360–2. Epub 1999/12/23. PMID: 10607725.
56. Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies. *Cell J*. 2015; 17(2):187–92.

- Epub 2015/07/23. <https://doi.org/10.22074/cellj.2016.3711> PMID: 26199897; PubMed Central PMCID: PMC4503832.
57. Perneger TV. What's wrong with Bonferroni adjustments. *BMJ*. 1998; 316(7139):1236–8. Epub 1998/05/16. <https://doi.org/10.1136/bmj.316.7139.1236> PMID: 9553006; PubMed Central PMCID: PMC1112991.
  58. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. 1990; 1(1):43–6. Epub 1990/01/01. PMID: 2081237.
  59. Rothman KJ. Six persistent research misconceptions. *J Gen Intern Med*. 2014; 29(7):1060–4. Epub 2014/01/24. <https://doi.org/10.1007/s11606-013-2755-z> PMID: 24452418; PubMed Central PMCID: PMC4061362.
  60. Kinyanjui SM, Howard T, Williams TN, Bull PC, Newbold CI, Marsh K. The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of *Plasmodium falciparum*-infected erythrocytes. *J Immunol Methods*. 2004; 288(1–2):9–18. Epub 2004/06/09. <https://doi.org/10.1016/j.jim.2004.01.022> S0022175904000638 [pii]. PMID: 15183081.
  61. Nery S, Deans AM, Mosobo M, Marsh K, Rowe JA, Conway DJ. Expression of *Plasmodium falciparum* genes involved in erythrocyte invasion varies among isolates cultured directly from patients. *Mol Biochem Parasitol*. 2006; 149(2):208–15. Epub 2006/07/14. <https://doi.org/10.1016/j.molbiopara.2006.05.014> [pii] PMID: 16837080.
  62. Adams S, Turner GD, Nash GB, Micklem K, Newbold CI, Craig AG. Differential binding of clonal variants of *Plasmodium falciparum* to allelic forms of intracellular adhesion molecule 1 determined by flow adhesion assay. *Infect Immun*. 2000; 68(1):264–9. Epub 1999/12/22. <https://doi.org/10.1128/IAI.68.1.264-269.2000> PMID: 10603397; PubMed Central PMCID: PMC97130.
  63. Baruch DI, Gormely JA, Ma C, Howard RJ, Pasloske BL. *Plasmodium falciparum* erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. *Proc Natl Acad Sci U S A*. 1996; 93(8):3497–502. Epub 1996/04/16. <https://doi.org/10.1073/pnas.93.8.3497> PMID: 8622965; PubMed Central PMCID: PMC39638.
  64. Roberts DJ, Craig AG, Berendt AR, Pinches R, Nash G, Marsh K, et al. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. *Nature*. 1992; 357(6380):689–92. Epub 1992/06/25. <https://doi.org/10.1038/357689a0> PMID: 1614515.
  65. Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. *Nature*. 1997; 388(6639):292–5. Epub 1997/07/17. <https://doi.org/10.1038/40888> PMID: 9230440.
  66. Springer AL, Smith LM, Mackay DQ, Nelson SO, Smith JD. Functional interdependence of the DBLbeta domain and c2 region for binding of the *Plasmodium falciparum* variant antigen to ICAM-1. *Mol Biochem Parasitol*. 2004; 137(1):55–64. Epub 2004/07/29. <https://doi.org/10.1016/j.molbiopara.2004.03.019> S0166685104001410 [pii]. PMID: 15279951.
  67. Ghumra A, Khunrae P, Ataide R, Raza A, Rogerson SJ, Higgins MK, et al. Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to *Plasmodium falciparum*. *PLoS One*. 2011; 6(1):e16414. Epub 2011/02/10. <https://doi.org/10.1371/journal.pone.0016414> PMID: 21305024; PubMed Central PMCID: PMC3031562.
  68. Ochola LB, Siddondo BR, Ocholla H, Nkya S, Kimani EN, Williams TN, et al. Specific receptor usage in *Plasmodium falciparum* cytoadherence is associated with disease outcome. *PLoS One*. 2011; 6(3):e14741. Epub 2011/03/11. <https://doi.org/10.1371/journal.pone.0014741> PMID: 21390226; PubMed Central PMCID: PMC3048392.
  69. Handunnetti SM, Gilladoga AD, van Schravendijk MR, Nakamura K, Aikawa M, Howard RJ. Purification and in vitro selection of rosette-positive (R+) and rosette-negative (R-) phenotypes of knob-positive *Plasmodium falciparum* parasites. *Am J Trop Med Hyg*. 1992; 46(4):371–81. Epub 1992/04/01. <https://doi.org/10.4269/ajtmh.1992.46.371> PMID: 1575284.
  70. Ribaut C, Berry A, Chevalley S, Reybier K, Mollais I, Parzy D, et al. Concentration and purification by magnetic separation of the erythrocytic stages of all human *Plasmodium* species. *Malar J*. 2008; 7:45. <https://doi.org/10.1186/1475-2875-7-45> PMID: 18321384; PubMed Central PMCID: PMC2292734.
  71. Paton D, Faragher B, Mustaffa KM, Szeszak T, Barrett SD, Craig AG. Automated counting for *Plasmodium falciparum* cytoadherence experiments. *Malar J*. 2011; 10:91. Epub 2011/04/19. <https://doi.org/10.1186/1475-2875-10-91> [pii] PMID: 21496305; PubMed Central PMCID: PMC3094228.
  72. Ghumra A, Semblat JP, Ataide R, Kifude C, Adams Y, Claessens A, et al. Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites. *PLoS Pathog*. 2012; 8(4):e1002665. Epub 2012/04/26. <https://doi.org/10.1371/journal.ppat.1002665> PPATHOGENS-D-11-02075 [pii]. PMID: 22532802; PubMed Central PMCID: PMC3330128.

73. Opi DH, Uyoga S, Orori EN, Williams TN, Rowe JA. Red blood cell complement receptor one level varies with Knops blood group, alphasphaemoglobinemia and age among Kenyan children. *Genes Immun*. 2016. Epub 2016/02/05. <https://doi.org/10.1038/gene.2016.2> PMID: 26844958.
74. Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor M, et al. A human complement receptor 1 polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria. *Proc Natl Acad Sci U S A*. 2004; 101(1):272–7. Epub 2003/12/25. <https://doi.org/10.1073/pnas.0305306101> [pii]. PMID: 14694201.
75. Rowe A, Berendt AR, Marsh K, Newbold CI. *Plasmodium falciparum*: a family of sulphated glycoconjugates disrupts erythrocyte rosettes. *Exp Parasitol*. 1994; 79(4):506–16. Epub 1994/12/01. <https://doi.org/10.1006/expr.1994.1111> [pii]. PMID: 8001661.
76. Fairhurst RM, Bess CD, Krause MA. Abnormal PfEMP1/knob display on *Plasmodium falciparum*-infected erythrocytes containing hemoglobin variants: fresh insights into malaria pathogenesis and protection. *Microbes Infect*. 2012. Epub 2012/05/29. <https://doi.org/10.1016/j.micinf.2012.05.006> [pii] PMID: 22634344.
77. Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, Wahlgren M. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. *Lancet*. 1990; 336(8729):1457–60. Epub 1990/12/15. [https://doi.org/10.1016/0140-6736\(90\)93174-n](https://doi.org/10.1016/0140-6736(90)93174-n) PMID: 1979090.
78. Handunnetti SM, David PH, Perera KL, Mendis KN. Uninfected erythrocytes form "rosettes" around *Plasmodium falciparum* infected erythrocytes. *The American journal of tropical medicine and hygiene*. 1989; 40(2):115–8. <https://doi.org/10.4269/ajtmh.1989.40.115> PMID: 2645800.
79. Udomsangpetch R, Wahlin B, Carlson J, Berzins K, Torii M, Aikawa M, et al. *Plasmodium falciparum*-infected erythrocytes form spontaneous erythrocyte rosettes. *J Exp Med*. 1989; 169(5):1835–40. Epub 1989/05/01. <https://doi.org/10.1084/jem.169.5.1835> PMID: 2654325.
80. Degarege A, Gebrezgi MT, Ibanez G, Wahlgren M, Madhivanan P. Effect of the ABO blood group on susceptibility to severe malaria: A systematic review and meta-analysis. *Blood Rev*. 2019; 33:53–62. Epub 2018/07/22. <https://doi.org/10.1016/j.blre.2018.07.002> PMID: 30029997.
81. Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakite SA, Arie T, et al. Impaired cytoadherence of *Plasmodium falciparum*-infected erythrocytes containing sickle hemoglobin. *Proc Natl Acad Sci U S A*. 2008; 105(3):991–6. Epub 2008/01/15. <https://doi.org/10.1073/pnas.0711401105> [pii] PMID: 18192399.
82. Mahamar A, Attaher O, Swihart B, Barry A, Diarra BS, Kanoute MB, et al. Host factors that modify *Plasmodium falciparum* adhesion to endothelial receptors. *Sci Rep*. 2017; 7(1):13872. Epub 2017/10/27. <https://doi.org/10.1038/s41598-017-14351-7> PMID: 29066816; PubMed Central PMCID: PMC5655674.
83. Pathak V, Colah R, Ghosh K. Correlation between 'H' blood group antigen and *Plasmodium falciparum* invasion. *Ann Hematol*. 2016; 95(7):1067–75. Epub 2016/04/14. <https://doi.org/10.1007/s00277-016-2663-5> PMID: 27071756.
84. Theron M, Cross N, Cawkill P, Bustamante LY, Rayner JC. An in vitro erythrocyte preference assay reveals that *Plasmodium falciparum* parasites prefer Type O over Type A erythrocytes. *Sci Rep*. 2018; 8(1):8133. Epub 2018/05/29. <https://doi.org/10.1038/s41598-018-26559-2> PMID: 29802282; PubMed Central PMCID: PMC5970199.
85. Wolofsky KT, Ayi K, Branch DR, Hult AK, Olsson ML, Liles WC, et al. ABO blood groups influence macrophage-mediated phagocytosis of *Plasmodium falciparum*-infected erythrocytes. *PLoS Pathog*. 2012; 8(10):e1002942. Epub 2012/10/17. <https://doi.org/10.1371/journal.ppat.1002942> PPATHOGENS-D-12-00992 [pii]. PMID: 23071435; PubMed Central PMCID: PMC3469569.
86. Quintana MDP, Ch'ng JH, Moll K, Zandian A, Nilsson P, Idris ZM, et al. Antibodies in children with malaria to PfEMP1, RIFIN and SURFIN expressed at the *Plasmodium falciparum* parasitized red blood cell surface. *Sci Rep*. 2018; 8(1):3262. Epub 2018/02/21. <https://doi.org/10.1038/s41598-018-21026-4> PMID: 29459776; PubMed Central PMCID: PMC5818650 Dilaforette), a company developing drugs for the treatment of severe malaria. All the other authors declared that they have no competing interests.
87. Olsson ML, Irshaid NM, Hosseini-Maaf B, Hellberg A, Moulds MK, Sareneva H, et al. Genomic analysis of clinical samples with serologic ABO blood grouping discrepancies: identification of 15 novel A and B subgroup alleles. *Blood*. 2001; 98(5):1585–93. Epub 2001/08/25. <https://doi.org/10.1182/blood.v98.5.1585> PMID: 11520811.
88. Yip SP. Sequence variation at the human ABO locus. *Ann Hum Genet*. 2002; 66(Pt 1):1–27. Epub 2002/05/17. <https://doi.org/10.1017/S0003480001008995> S0003480001008995 [pii]. PMID: 12014997.
89. Chester MA, Olsson ML. The ABO blood group gene: a locus of considerable genetic diversity. *Transfus Med Rev*. 2001; 15(3):177–200. Epub 2001/07/27. <https://doi.org/10.1053/tmrv.2001.24591> PMID: 11471121.

90. Cartron JP, Gerbal A, Hughes-Jones NC, Salmon C. 'Weak A' phenotypes. Relationship between red cell agglutinability and antigen site density. *Immunology*. 1974; 27(4):723–7. Epub 1974/10/01. PMID: [4435836](#); PubMed Central PMCID: PMC1445712.
91. Heier HE, Kornstad L, Namork E, Ostgard P, Sandin R. Expression of B and H antigens on red cells from a group B(weak) individual studied by serologic and scanning electron microscopic techniques. *Immunohematology*. 1992; 8(4):94–9. Epub 1992/12/01. PMID: [15946069](#).
92. Heier HE, Namork E, Calkovska Z, Sandin R, Kornstad L. Expression of A antigens on erythrocytes of weak blood group A subgroups. *Vox Sang*. 1994; 66(3):231–6. Epub 1994/01/01. <https://doi.org/10.1111/j.1423-0410.1994.tb00315.x> PMID: [8036794](#).
93. Ogasawara K, Yabe R, Uchikawa M, Nakata K, Watanabe J, Takahashi Y, et al. Recombination and gene conversion-like events may contribute to ABO gene diversity causing various phenotypes. *Immunogenetics*. 2001; 53(3):190–9. Epub 2001/06/12. <https://doi.org/10.1007/s002510100315> PMID: [11398963](#).
94. Roubinet F, Despiau S, Calafell F, Jin F, Bertranpetit J, Saitou N, et al. Evolution of the O alleles of the human ABO blood group gene. *Transfusion*. 2004; 44(5):707–15. Epub 2004/04/24. <https://doi.org/10.1111/j.1537-2995.2004.03346.x> PMID: [15104652](#).